BioNxt Solutions Prepares for Human Bioequivalence Study For MS

BioNxt Solutions Prepares for Human Bioequivalence Study For MS

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for…

BioNxt Solutions Prepares for Human Bioequivalence Study For MS - European Business & Finance Magazine

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt’s lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment …

Disease activity test helps with MS care decisions: Study

Assessing multiple sclerosis (MS) disease activity using Octave Bioscience’s MS Disease Activity (MSDA) blood biomarker test can help guide clinicians’ decisions about care, a study showed. “Our goal is to […] The post Disease activity test helps with MS care decisions: Study appeared first on Multiple Sclerosis News Today.